Published in J Ophthalmic Vis Res on September 13, 2016
Age-related macular degeneration. Lancet (2012) 4.17
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 3.19
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 3.03
An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol (1991) 3.02
Does surgical experience have an effect on the success of retinal detachment surgery? Retina (2012) 2.22
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia (2005) 2.09
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Regulation of scar formation by vascular endothelial growth factor. Lab Invest (2008) 1.51
Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond) (2002) 1.32
Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol (2004) 1.30
Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci (2009) 1.23
Regulating the angiogenic balance in tissues. Cell Cycle (2008) 1.13
Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res (2014) 1.12
Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment (SPR Study): design issues and implications. SPR Study report no. 1. Graefes Arch Clin Exp Ophthalmol (2001) 1.09
Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS One (2011) 1.04
Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol (2000) 1.02
Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol (2013) 0.98
Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res (2007) 0.96
Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol (2013) 0.96
Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol (2002) 0.95
Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res (2011) 0.93
Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol (2010) 0.93
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye Res (2010) 0.87
Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol (2008) 0.85
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev (2010) 0.85
Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study. Br J Ophthalmol (2012) 0.84
Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol (1986) 0.80
Recurrent Vitreous Hemorrhage in a Case of Retinal Cavernous Hemangioma: A Rare Presentation. J Ophthalmic Vis Res (2016) 0.75
Unilateral Keratectasia Treated with Femtosecond Fashioned Intrastromal Corneal Inlay. J Ophthalmic Vis Res (2017) 0.75